
  
    
      
        Background_NNP
        Sucrase-isomaltase_NNP (_( SI_NNP ,_, EC_NNP 3_CD ._. 2_CD ._. 1_LS ._. 48_CD )_) is_VBZ an_DT
        enterocyte-specific_JJ small_JJ intestine_NN brush-border_JJ membrane_NN
        disaccharidase_NN ._. It_PRP is_VBZ required_VBN for_IN hydrolysis_NNS of_IN dietary_JJ
        sucrose_NN and_CC some_DT starches_NNS ._. Because_IN absorption_NN cannot_NN take_NN
        place_NN until_IN monosaccharides_NNS are_VBP produced_VBN ,_, SI_NNP deficiency_NN
        leads_VBZ to_TO increased_VB luminal_NN disaccharides_NNS and_CC consequent_JJ
        osmotic_JJ diarrhea_NN ._. Although_IN generally_RB thought_VBD to_TO have_VB a_DT
        later_JJ presentation_NN [_NN 1_CD ]_NN than_IN other_JJ primary_JJ intestinal_NN
        malabsorption_NN syndromes_NNS ,_, recent_JJ reports_NNS of_IN infants_NNS with_IN SI_NNP
        deficiency_NN indicate_VBP the_DT existence_NN of_IN an_DT early_JJ onset_NN form_NN
        (_( presentation_NN of_IN diarrhea_NN at_IN 2_CD -_: 16_CD weeks_NNS )_) that_WDT is_VBZ
        complicated_VBN by_IN severe_JJ malnutrition_NN [_NN 2_CD ]_NN ._. Starnes_NNP and_CC
        Walsh_NNP [_NN 3_CD ]_NN observed_VBD renal_JJ calculi_NN in_IN two_CD adults_NNS with_IN
        sucrase_NN deficiency_NN ,_, but_CC neither_DT patient_NN had_VBD evidence_NN of_IN
        hypercalcemia_NN ._. In_IN contrast_NN ,_, hypercalcemia_NN frequently_RB
        complicates_VBZ congenital_NN lactase_NN deficiency_NN [_NN 4_CD ]_NN ._. The_DT
        present_JJ case_NN illustrates_VBZ the_DT occurrence_NN of_IN hypercalcemia_NN
        and_CC nephrocalcinosis_NNS as_IN a_DT clinically_RB significant_JJ
        complication_NN of_IN SI_NNP deficiency_NN in_IN an_DT infant_NN and_CC suggests_VBZ
        that_IN common_JJ mechanisms_NNS may_MD lead_VB to_TO hypercalcemia_NN in_IN both_DT SI_NNP
        and_CC congenital_NN lactase_NN deficiency_NN ._.
      
      
        Case_NNP Presentation_NNP
        The_DT patient_NN was_VBD a_DT 10_CD month_NN old_JJ caucasian_NN female_JJ infant_NN
        presenting_VBG with_IN failure_NN to_TO thrive_VB (_( FTT_NNP )_) ,_, metabolic_JJ
        acidosis_NNS ,_, and_CC hypercalcemia_NN ._. She_PRP was_VBD the_DT product_NN of_IN a_DT term_NN
        uncomplicated_JJ pregnancy_NN in_IN a_DT 31_CD -_: year-old_JJ and_CC delivered_VBN
        without_IN complications_NNS ._. She_PRP had_VBD been_VBN growing_VBG well_RB and_CC
        thriving_VBG until_IN weaned_JJ from_IN breast_NN milk_NN to_TO formula_NN at_IN age_NN 4_CD
        months_NNS when_WRB she_PRP began_VBD to_TO have_VB frequent_JJ stools_NNS and_CC poor_JJ
        weight_NN gain_NN ._. Formula_NNP and_CC diet_NN changes_NNS were_VBD attempted_VBN
        without_IN improvement_NN ._. She_PRP was_VBD seen_VBN by_IN a_DT pediatric_JJ
        gastroenterologist_NN and_CC underwent_VBD colonoscopy_NN ,_, a_DT biopsy_NN from_IN
        which_WDT showed_VBD eosinophilic_JJ inflammation_NN ._. Upper_NNP GI_NNP tract_NN
        endoscopy_NN was_VBD interrupted_VBN because_IN of_IN sedation_NN problems_NNS ._. She_PRP
        was_VBD treated_VBN with_IN glucocorticoids_NNS and_CC her_PRP$ formula_NN was_VBD
        changed_VBN to_TO Neocate_NNP (_( 49_CD mg_NN Ca_MD /_NN 100_CD mL_NN )_) with_IN some_DT initial_JJ
        improvement_NN ._. The_DT glucocorticoids_NNS were_VBD discontinued_VBN at_IN age_NN 9_CD
        months_NNS but_CC she_PRP still_RB gained_VBD weight_NN poorly_RB ;_: routine_JJ
        chemistry_NN analyses_NNS showed_VBD evolving_VBG hypercalcemia_NN
        (_( outpatient_NN calcium_NN peak_NN 13_CD ._. 7_CD mg_NN /_NN dL_NN ,_, Figure_NN 1_LS )_) and_CC
        persistent_JJ metabolic_JJ acidosis_NNS ._. She_PRP was_VBD admitted_VBN to_TO the_DT
        hospital_NN for_IN evaluation_NN and_CC treatment_NN of_IN hypercalcemia_NN ,_,
        FTT_NNP ,_, and_CC metabolic_JJ acidosis_NNS ._.
        Other_JJ than_IN skin_NN changes_NNS consistent_JJ with_IN wasting_NN ,_, her_PRP$
        examination_NN was_VBD benign_JJ ._. There_EX was_VBD no_DT abnormal_JJ flatus_JJ or_CC
        bloating_VBG ,_, but_CC there_EX had_VBD been_VBN intermittent_JJ blood_NN in_IN the_DT
        stool_NN with_IN some_DT mucous_JJ ._. Laboratory_NN studies_NNS are_VBP shown_VBN in_IN
        Table_NNP 1_CD ._. The_DT intact_JJ parathyroid_NN hormone_NN (_( PTH_NNP )_) was_VBD
        appropriately_RB suppressed_VBN to_TO 6_CD pg_NN /_NN mL_NN with_IN concomitant_NN serum_NN
        calcium_NN of_IN 13_CD ._. 8_CD mg_NN /_NN dL_NN and_CC ionized_JJ calcium_NN (_( Ca_MD 2_CD +_NN )_) 1_CD ._. 98_CD
        mmol_NN /_NN L_NNP (_( normal_JJ 1_CD ._. 20_CD -_: 1_CD ._. 38_CD )_) ;_: other_JJ pertinent_JJ laboratory_NN
        values_NNS included_VBD :_: phosphorus_JJ 5_CD ._. 7_CD mg_NN /_NN dL_NN ;_: magnesium_NN 2_CD ._. 6_CD mg_NN /_NN dL_NN ;_:
        alkaline_NN phosphatase_NN 79_CD IU_NNP /_NN L_NNP ;_: PTH-related_NNP peptide_NN (_( PTH-rp_NNP )_)
        appropriately_RB undetectable_JJ at_IN <_NN 0_CD ._. 2_LS pmol_NN /_NN L_NNP (_( normal_JJ <_NN
        2_CD ._. 8_CD )_) ;_: 25_CD -_: hydroxy_NN Vitamin_NNP D_NNP 16_CD ng_NN /_NN mL_NN (_( reference_NN lab_NN normal_JJ
        range_NN for_IN age_NN 3_CD -_: 17_CD years_NNS =_SYM 13_CD -_: 67_CD )_) ;_: and_CC 1_CD ,_, 25_CD -_: dihydroxy_NN
        Vitamin_NNP D_NNP level_NN 32_CD pg_NN /_NN mL_NN (_( reference_NN lab_NN normal_JJ range_NN for_IN
        age_NN 3_CD -_: 17_CD years_NNS =_SYM 27_CD -_: 71_CD )_) ._. The_DT urine_NN calcium_NN was_VBD 11_CD ._. 9_CD mg_NN /_NN dL_NN
        with_IN urine_NN creatinine_NN <_NN 10_CD mg_NN /_NN dL_NN ._. Renal_NNP ultrasound_NN
        demonstrated_VBD nephrocalcinosis_NNS ._. The_DT hemi-skeletal_JJ bone_NN age_NN
        was_VBD interpreted_VBN to_TO be_VB delayed_VBN to_TO that_DT of_IN a_DT 3_CD -_: 6_CD month_NN old_JJ ._.
        Stools_NNP were_VBD positive_JJ for_IN leukocytes_NNS and_CC trace_VB reducing_VBG
        substances_NNS ._. Normal_NNP karyotype_NN and_CC normal_JJ fluorescent_NN in-situ_JJ
        hybridization_NN (_( FISH_NNP )_) for_IN the_DT elastin_NN gene_NN locus_JJ on_IN
        chromosome_NN 7_CD (_( 46_CD ,_, XX_NNP ,_, negative_JJ ELN_NNP 7_CD q_NN 11_CD ._. 23_CD )_) along_IN with_IN a_DT
        negative_JJ echocardiogram_NN helped_VBD exclude_VB Williams_NNP syndrome_NN ._.
        She_PRP initially_RB was_VBD treated_VBN with_IN intravenous_JJ normal_JJ saline_NN
        followed_VBN by_IN furosemide_NN with_IN only_RB transient_JJ improvement_NN ._.
        Recurrent_NNP hypercalcemia_NN prompted_VBD a_DT 3_CD -_: day_NN course_NN of_IN
        intravenous_JJ pamidronate_NN (_( 0_CD ._. 5_LS mg_NN /_NN kg_NN per_IN dose_NN )_) leading_VBG to_TO
        sustained_VBN high-normal_JJ serum_NN calcium_NN (_( Figure_NN 1_LS )_) ._. She_PRP was_VBD
        discharged_VBN home_NN ._. She_PRP was_VBD empirically_RB treated_VBN with_IN
        Polycitra_NNP ™_NN for_IN the_DT persistent_JJ metabolic_JJ acidosis_NNS ,_, but_CC
        on-going_JJ FTT_NNP prompted_VBD reevaluation_NN ._.
        At_IN time_NN of_IN second_JJ admission_NN the_DT infant_NN was_VBD taking_VBG
        Neocate_NNP supplemented_JJ with_IN 5_CD jars_NNS of_IN baby_NN food_NN fruits_NNS per_IN
        day_NN plus_CC Polycitra_NNP ™_NN ._. Gross_JJ motor_NN development_NN was_VBD delayed_VBN
        but_CC other_JJ developmental_NN axes_NNS were_VBD intact_JJ ._. Family_NN history_NN
        was_VBD significant_JJ for_IN Hashimoto_NNP 's_POS thyroiditis_NNS in_IN the_DT mother_NN ,_,
        maternal_NN aunt_NN ,_, and_CC maternal_NN grandfather_NN ._. The_DT parents_NNS were_VBD
        both_DT of_IN European_JJ ethnic_JJ origin_NN and_CC there_EX was_VBD no_DT
        consanguinity_NN ._. Physical_JJ examination_NN showed_VBD an_DT alert_NN ,_,
        nondysmorphic_JJ infant_NN with_IN severe_JJ reduction_NN in_IN muscle_NN mass_NN
        and_CC subcutaneous_JJ fat_NN ._. Frequent_JJ loose_JJ watery_JJ stools_NNS were_VBD
        noted_VBN ._. A_DT skeletal_NN survey_NN showed_VBD striking_JJ linear_JJ bone_NN
        density_NN increase_NN in_IN the_DT epiphyses_NNS in_IN an_DT area_NN adjacent_JJ to_TO
        the_DT growth_NN plate_NN (_( Figure_NN 2_CD A_DT )_) ._. Follow_VB up_RB admission_NN
        laboratory_NN studies_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._. Specifically_RB ,_, the_DT
        calcitonin_NN was_VBD 9_CD ._. 9_CD pg_NN /_NN mL_NN (_( normal_JJ <_NN 12_CD )_) and_CC the_DT Vitamin_NNP A_DT
        concentration_NN was_VBD 33_CD μg_NN /_NN dL_NN (_( 20_CD -_: 43_CD )_) ._. The_DT urine_NN calcium_NN was_VBD
        11_CD ._. 1_LS mg_NN /_NN dL_NN and_CC calcium_NN /_NN creatinine_NN ratio_NN of_IN 2_CD ._. 8_CD ._. EKG_NNP showed_VBD
        a_DT normal_JJ QTc_NNP ._. Renal_NNP ultrasound_NN confirmed_VBD nephrocalcinosis_NNS
        (_( Figure_NN 2_CD B_NNP )_) ._. Upper_NNP endoscopy_NN with_IN biopsy_NN revealed_VBD areas_NNS of_IN
        mild_JJ focal_JJ chronic_JJ inflammatory_JJ cells_NNS in_IN the_DT stomach_NN ._.
        Colonoscopy_NNP showed_VBD no_DT bowel_NN wall_NN inflammation_NN but_CC copious_JJ
        watery_JJ stool_NN ._. Stool_NNP sodium_NN was_VBD 17_CD mmol_NN /_NN L_NNP ._.
        The_DT persistence_NN of_IN hypercalcemia_NN with_IN diarrhea_NN prompted_VBD
        a_DT nuclear_JJ medicine_NN scan_VB with_IN 1_CD ._. 5_CD mCi_NN of_IN 111_CD indium_NN
        pentetreotide_NN to_TO pursue_VB a_DT possible_JJ paraneoplastic_JJ process_NN [_NN
        5_CD ]_NN which_WDT showed_VBD uptake_NN in_IN the_DT right_JJ orbital_NN region_NN ._. A_DT head_JJ
        CT_NNP and_CC MRI_NNP demonstrated_VBD an_DT infiltrating_VBG lesion_NN in_IN the_DT right_JJ
        orbit_NN along_IN the_DT inferior_JJ and_CC lateral_NN compartment_NN of_IN the_DT
        orbit_NN involving_VBG the_DT intra-_NN and_CC extra-coronal_JJ space_NN ._. There_EX
        was_VBD no_DT obvious_JJ lytic_JJ change_NN or_CC periostosis_NNS ;_: however_RB ,_, there_EX
        were_VBD flow_NN voids_NNS consistent_JJ with_IN a_DT vascular_NN malformation_NN ._. No_DT
        abnormalities_NNS in_IN extraocular_NN movements_NNS ,_, globe_NN ,_, or_CC retina_NN
        were_VBD observed_VBN ._. These_DT findings_NNS were_VBD interpreted_VBN as_IN
        consistent_JJ with_IN a_DT benign_JJ orbital_NN hemangioma_NN ._. Serial_JJ follow_VB
        up_RP studies_NNS confirm_VBP that_IN the_DT lesion_NN is_VBZ not_RB growing_VBG ;_: indeed_RB
        there_EX is_VBZ evidence_NN of_IN fatty_NN involution_NN ._.
        Small_JJ bowel_NN biopsies_NNS taken_VBN at_IN the_DT time_NN of_IN endoscopy_NN
        revealed_VBD :_: lactase_NN 34_CD ._. 6_CD μM_NN /_NN min_NN /_NN g_SYM (_( 24_CD ._. 5_LS +_NN /_NN -_: 18_CD ,_, abnormal_JJ less_JJR
        than_IN 15_CD )_) ,_, sucrase_NN 0_CD μM_NN /_NN min_NN /_NN g_SYM (_( 54_CD ._. 4_LS +_NN /_NN -_: 25_CD ._. 4_LS ,_, abnormal_JJ less_JJR
        than_IN 25_CD )_) ,_, maltase_NN 22_CD ._. 7_CD μM_NN /_NN min_NN /_NN g_SYM (_( 160_CD ._. 8_CD +_NN /_NN -_: 52_CD ._. 8_CD ,_, abnormal_JJ
        less_JJR than_IN 100_CD )_) leading_VBG to_TO the_DT diagnosis_NN of_IN
        sucrase-isomaltase_JJ deficiency_NN ._. Sucrose_NNP free_JJ diet_NN with_IN
        Sucraid_NNP ™_NN enzyme_NN replacement_NN was_VBD prescribed_VBN followed_VBN by_IN
        changing_VBG feeds_VBZ to_TO 3232_CD A_DT base_NN formula_NN with_IN supplemental_JJ
        anhydrous_JJ dextrose_NN (_( Ca_MD 94_CD mg_NN /_NN 100_CD mL_NN )_) resulting_VBG in_IN a_DT prompt_JJ
        cessation_NN of_IN diarrhea_NN ._. Urine_NNP calcium_NN /_NN creatinine_NN ratio_NN
        decreased_VBD to_TO 0_CD ._. 58_CD ._. Her_PRP$ weight_NN has_VBZ steadily_RB improved_VBN (_( Figure_NN
        3_LS )_) ._. Residual_NNP muscle_NN weakness_NN in_IN the_DT lower_JJR extremities_NNS is_VBZ
        being_VBG treated_VBN with_IN physical_JJ therapy_NN ._.
      
      
        Causes_NNP of_IN hypercalcemia_NN in_IN infancy_NN
        An_DT extensive_JJ evaluation_NN of_IN our_PRP$ patient_NN failed_VBD to_TO
        identify_VB any_DT abnormality_NN in_IN calcium_NN regulation_NN ._. It_PRP should_MD
        be_VB emphasized_VBN that_IN our_PRP$ patient_NN demonstrated_VBD
        nephrocalcinosis_NNS prior_RB to_TO alkalinization_NN with_IN Polycitra_NNP ™_NN to_TO
        combat_VB her_PRP$ metabolic_JJ acidosis_NNS ._. Urine_NNP alkalinization_NN is_VBZ a_DT
        common_JJ strategy_NN to_TO treat_VB urate_NN and_CC cysteine_NN renal_JJ stones_NNS ._.
        Animal_NNP and_CC preliminary_JJ human_JJ studies_NNS suggest_VBP acid-phosphate_JJ
        replacement_NN (_( vs_NNS ._. neutral-phosphate_JJ therapy_NN )_) is_VBZ of_IN equal_JJ
        benefit_NN and_CC does_VBZ not_RB perturb_NN calcium_NN /_NN phosphorus_JJ metabolism_NN
        in_IN children_NNS with_IN phosphate-wasting_JJ rickets_NNS [_NN 6_CD ]_NN ._. Infants_NNS
        with_IN hypercalcemia_NN may_MD have_VB no_DT obvious_JJ symptoms_NNS ,_, but_CC
        constitutional_JJ symptoms_NNS such_JJ as_IN poor_JJ appetite_NN ,_,
        irritability_NN ,_, vomiting_NN ,_, FTT_NNP ,_, or_CC occasionally_RB seizures_NNS may_MD
        occur_VB [_NN 7_CD ]_NN ._. Classically_NNP ,_, hypercalcemia_NN leads_VBZ to_TO increased_VB
        urine_NN output_NN and_CC diminished_VBN stool_NN frequency_NN ._. Physical_JJ signs_NNS
        may_MD include_VB hypotonia_NN ,_, dehydration_NN ,_, and_CC bradycardia_NN ._.
        Laboratory_NN abnormalities_NNS can_MD include_VB short_JJ QTc_NNP and_CC elevated_VBD
        creatinine_NN ._. Increased_VBN urinary_JJ calcium_NN is_VBZ an_DT expected_VBN
        compensatory_JJ response_NN with_IN associated_VBN increased_VBN risk_NN of_IN
        renal_JJ calculi_NN ._. The_DT differential_NN diagnosis_NN of_IN hypercalcemia_NN
        in_IN infants_NNS includes_VBZ hyperparathyroidism_NN ,_, familial_NN
        hypocalciuric_JJ hypercalcemia_NN ,_, hypervitaminosis_NNS ,_,
        paraneoplastic_JJ processes_NNS ,_, and_CC Williams_NNP syndrome_NN ._.
        Hyperparathyroidism_NNP may_MD be_VB either_CC sporadic_JJ or_CC familial_NN
        arising_VBG from_IN either_DT adenoma_NN or_CC parathyroid_NN hyperplasia_NN ._.
        Familial_NNP hyperparathyroidism_NN may_MD be_VB confined_VBN to_TO parathyroid_NN
        adenoma_NN (_( HRPT_NNP 1_CD #_# 145000_CD )_) or_CC may_MD involve_VB the_DT broader_JJR
        endocrine_NN disturbances_NNS of_IN multiple_JJ endocrine_NN neoplasia_NN
        Types_NNP I_PRP (_( #_# 131100_CD )_) and_CC IIA_NNP (_( #_# 171400_CD )_) ._. MENI_NNP results_NNS from_IN
        mutations_NNS in_IN menin_NN ,_, a_DT regulator_NN of_IN TGFβ_NNP signaling_VBG in_IN a_DT
        variety_NN of_IN tissues_NNS [_NN 8_CD ]_NN ._. MENIIA_NNP results_NNS form_VBP mutations_NNS in_IN
        RET_NNP a_DT cell_NN surface_NN growth_NN factor_NN receptor_NN with_IN intrinsic_JJ
        tyrosine_NN kinase_NN activity_NN [_NN 9_CD ]_NN ._. Familial_NNP hypocalciuric_JJ
        hypercalcemia_NN (_( #_# 145980_CD )_) ,_, generally_RB autosomal_NN dominant_JJ and_CC
        caused_VBN by_IN mutations_NNS in_IN the_DT renal_JJ calcium_NN sensing_VBG receptor_NN [_NN
        10_CD 11_CD ]_NN ,_, is_VBZ excluded_VBN rather_RB easily_RB based_VBN on_IN urinary_JJ
        calcium_NN levels_NNS of_IN the_DT patient_NN and_CC parents_NNS ._.
        Both_DT hypervitaminoses_NNS D_NNP and_CC A_DT are_VBP potential_JJ causes_NNS of_IN
        hypercalcemia_NN ._. Prolonged_NNP feeding_NN with_IN over_IN fortified_VBN milk_NN
        or_CC vitamin_NN preparations_NNS has_VBZ been_VBN reported_VBN as_IN sources_NNS of_IN
        excess_JJ intake_NN of_IN vitamin_NN D_NNP ._. Abnormal_NNP vitamin_NN D_NNP metabolism_NN
        resulting_VBG from_IN inflammatory_JJ diseases_NNS such_JJ as_IN sarcoidosis_NNS or_CC
        tuberculosis_NNS or_CC as_IN seen_VBN in_IN neonatal_NN fat_JJ necrosis_NNS are_VBP
        additional_JJ potential_JJ causes_NNS ,_, albeit_IN highly_RB unlikely_JJ in_IN
        young_JJ infants_NNS [_NN 12_CD ]_NN ._. The_DT mechanism_NN is_VBZ thought_VBN to_TO be_VB due_JJ
        to_TO increased_VBD 1_CD á-hydroxylase_JJ activity_NN leading_VBG to_TO increased_VBN
        production_NN of_IN 1_CD ,_, 25_CD -_: dihydroxy_NN Vitamin_NNP D_NNP ._.
        While_IN neoplasia_NN with_IN osseous_JJ metastasis_NNS is_VBZ a_DT potential_JJ
        cause_NN of_IN hypercalcemia_NN ,_, tumors_NNS may_MD also_RB secrete_NN materials_NNS
        such_JJ as_IN PTH-rp_NNP or_CC other_JJ osteoclast-activating_JJ factors_NNS ,_,
        cytokines_NNS ,_, or_CC other_JJ growth_NN factors_NNS that_WDT modulate_VBP bone_NN
        remodeling_VBG leading_VBG to_TO calcium_NN adsorption_NN from_IN bone_NN ._. Chronic_NNP
        immobilization_NN can_MD also_RB lead_VB to_TO enhanced_JJ bone_NN
        resorption_NN ._.
        Williams_NNP syndrome_NN is_VBZ a_DT well_RB described_VBN birth_NN defect_NN
        complex_JJ characterized_VBN by_IN FTT_NNP ,_, branch_NN pulmonary_JJ artery_NN
        stenosis_NNS ,_, supravalvular_NN aortic_JJ stenosis_NNS ,_, dysmorphic_JJ facies_NNS ,_,
        mental_JJ retardation_NN ,_, and_CC infantile_JJ hypercalcemia_NN ._. Williams_NNP
        syndrome_NN results_NNS from_IN a_DT constitutional_JJ deletion_NN in_IN
        chromosome_NN 7_CD q_NN 11_CD ._. 23_CD [_NN 13_CD ]_NN ._. The_DT cause_NN of_IN hypercalcemia_NN
        associated_VBN with_IN Williams_NNP syndrome_NN is_VBZ not_RB well_RB understood_VBN
        but_CC has_VBZ been_VBN postulated_JJ to_TO be_VB associated_VBN with_IN enhanced_JJ
        intestinal_NN absorption_NN of_IN calcium_NN ._. The_DT presence_NN or_CC absence_NN
        of_IN significant_JJ hypercalcemia_NN does_VBZ not_RB correlate_VBP with_IN the_DT
        deletion_NN size_NN [_NN 14_CD ]_NN ._.
      
      
        Sucrase-isomaltase_NNP deficiency_NN
        Sucrase-isomaltase_NNP deficiency_NN is_VBZ a_DT rare_JJ autosomal_NN
        recessive_JJ disorder_NN in_IN which_WDT there_EX is_VBZ complete_JJ absence_NN of_IN
        sucrase_NN and_CC most_JJS of_IN the_DT maltase_NN digestive_JJ activity_NN ._. The_DT
        usual_JJ presentation_NN generally_RB is_VBZ at_IN weaning_VBG from_IN breast_NN milk_NN
        when_WRB infants_NNS are_VBP first_RB exposed_VBN to_TO the_DT offending_VBG
        carbohydrates_NNS [_NN 15_CD 16_CD 17_CD ]_NN ._. Upon_IN ingestion_NN of_IN
        disaccharides_NNS and_CC oligosaccharides_NNS ,_, the_DT failure_NN to_TO
        breakdown_NN sucrose_NN into_IN fructose_NN and_CC glucose_NN results_NNS in_IN an_DT
        osmotic-fermentative_JJ diarrhea_NN ._. Occasional_NNP patients_NNS may_MD come_VB
        to_TO attention_NN in_IN late_JJ childhood_NN or_CC adulthood_NN but_CC careful_JJ
        history_NN often_RB indicates_VBZ that_IN symptoms_NNS have_VBP appeared_VBN earlier_JJR
        [_NN 18_CD 19_CD ]_NN ._. The_DT mainstay_NN of_IN treatment_NN is_VBZ dietary_JJ
        restriction_NN of_IN sucrose-containing_JJ foods_NNS ._. Effective_NNP enzyme_NN
        replacement_NN with_IN whole_JJ yeast_NN cells_NNS has_VBZ been_VBN reported_VBN [_NN 20_CD ]_NN
        ._. Purified_NNP yeast_NN enzyme_NN ,_, sacrosidase_NN ,_, is_VBZ a_DT highly_RB effective_JJ
        adjunct_NN to_TO dietary_JJ restriction_NN [_NN 21_CD ]_NN ._.
        The_DT enzyme_NN itself_PRP is_VBZ composed_VBN of_IN 1827_CD amino_JJ acids_NNS
        encoded_JJ by_IN a_DT 3364_CD bp_NN mRNA_NN ._. The_DT gene_NN locus_JJ has_VBZ 30_CD exons_NNS
        spanning_VBG 106_CD ._. 6_CD kB_NN ._. Pro-_NNP SI_NNP is_VBZ anchored_VBN in_IN the_DT membrane_NN by_IN a_DT
        20_CD amino_JJ acid_NN membrane-spanning_JJ segment_NN ._. This_DT is_VBZ followed_VBN
        by_IN a_DT 22_CD amino_JJ acid_NN stalk_NN on_IN which_WDT sit_VBP the_DT 2_CD globular_NN
        catalytic_JJ domains_NNS ._. The_DT catalytic_JJ domains_NNS are_VBP similar_JJ to_TO one_CD
        another_DT (_( 41_CD %_NN amino_JJ acid_NN identity_NN )_) indicating_VBG that_IN they_PRP have_VBP
        arisen_VBN by_IN duplication_NN and_CC divergence_NN [_NN 22_CD ]_NN ._. One_CD estimate_NN
        indicated_VBD a_DT 2_CD %_NN mutant_JJ heterozygote_NN frequency_NN in_IN European_NNP
        Americans_NNPS [_NN 23_CD ]_NN but_CC ,_, given_VBN the_DT rarity_NN of_IN diagnosed_VBN SI_NNP
        deficiency_NN ,_, this_DT seems_VBZ high_JJ ._. Sucrase_NNP deficiency_NN may_MD be_VB
        especially_RB common_JJ in_IN indigenous_JJ Greenlanders_NNP (_( estimated_VBN 5_CD %_NN )_)
        and_CC is_VBZ accompanied_VBN most_RBS often_RB by_IN lactase_NN deficiency_NN [_NN 24_CD 25_CD
        ]_NN ._. Initial_JJ studies_NNS demonstrated_VBN that_IN most_JJS SI_NNP mutations_NNS
        result_VBP in_IN lack_NN of_IN enzyme_NN protein_NN (_( i_NNP ._. e_SYM ._. null_NN mutation_NN )_) [_NN 26_CD
        ]_NN ._. Mutation_NNP may_MD alter_VB the_DT post-translational_JJ processing_NN of_IN
        the_DT enzyme_NN only_RB for_IN the_DT asparagines-linked_JJ high-mannose_JJ
        groups_NNS but_CC not_RB the_DT mature_VB oligosaccharides_NNS ._. The_DT resulting_VBG
        enzyme_NN is_VBZ both_DT mislocalized_JJ and_CC unstable_JJ [_NN 27_CD ]_NN ._. Another_DT
        mutation_NN ,_, Q_NNP 1098_CD P_NN ,_, was_VBD found_VBN to_TO cause_VB retention_NN of_IN SI_NNP in_IN the_DT
        transport_NN pathway_NN between_IN the_DT endoplasmic_JJ reticulum_NN and_CC
        Golgi_NNP apparatus_NN [_NN 28_CD ]_NN ._. An_DT unusual_JJ mutation_NN ,_, Q_NNP 117_CD R_NN ,_, that_IN
        alters_NNS the_DT structure_NN close_RB to_TO the_DT O-_NNP glycosylated_JJ stalk_NN
        domain_NN ,_, leads_VBZ to_TO random_JJ distribution_NN of_IN the_DT enzyme_NN to_TO both_DT
        the_DT apical_JJ and_CC basolateral_NN cell_NN membranes_NNS [_NN 29_CD ]_NN ._. An_DT
        unusual_JJ human_JJ mutation_NN that_IN causes_NNS SI_NNP to_TO be_VB secreted_JJ rather_RB
        than_IN retained_VBD in_IN the_DT plasma_NN membrane_NN demonstrates_VBZ that_IN the_DT
        enzyme_NN is_VBZ required_VBN to_TO be_VB at_IN the_DT enterocyte_NN cell_NN surface_NN [_NN
        30_CD ]_NN ._.
      
      
        Disaccharidase_NNP deficiency_NN and_CC hypercalcemia_NN
        A_DT single_JJ case_NN report_NN potentially_RB relates_VBZ SI_NNP deficiency_NN
        with_IN disturbance_NN of_IN calcium_NN metabolism_NN ._. In_IN that_DT study_NN ,_, two_CD
        adults_NNS presented_VBN with_IN renal_JJ calculi_NN and_CC nephrocalcinosis_NNS [_NN
        3_CD ]_NN ._. Lactase_NNP deficiency_NN may_MD give_VB rise_NN to_TO metabolic_JJ bone_NN
        disease_NN [_NN 31_CD ]_NN ._. More_RBR pertinently_RB ,_, Saarela_NNP et_CC al_NN described_VBD
        7_CD of_IN 10_CD infants_NNS with_IN congenital_NN lactase_NN deficiency_NN who_WP had_VBD
        hypercalcemia_NN at_IN the_DT time_NN of_IN initial_JJ presentation_NN [_NN 4_CD ]_NN ._.
        Five_CD of_IN these_DT 7_CD infants_NNS had_VBD medullary_JJ nephrocalcinosis_NNS ._. The_DT
        mechanism_NN by_IN which_WDT congenital_NN lactase_NN deficiency_NN induces_VBZ
        hypercalcemia_NN is_VBZ uncertain_JJ ._. There_EX may_MD be_VB roles_NNS for_IN chronic_JJ
        metabolic_JJ acidosis_NNS and_CC dehydration_NN in_IN promoting_VBG both_DT
        increased_VBN bone_NN mobilization_NN of_IN calcium_NN and_CC thus_RB increasing_VBG
        the_DT risk_NN of_IN renal_JJ deposition_NN ._. Non-hydrolyzed_NNP lactose_NN may_MD
        also_RB exert_VB a_DT direct_JJ enhancing_VBG effect_NN on_IN calcium_NN absorption_NN
        in_IN the_DT ileum_NN ._. In_IN other_JJ conditions_NNS with_IN chronic_JJ diarrhea_NN ,_,
        such_JJ as_IN inflammatory_JJ bowel_NN disease_NN ,_, renal_JJ stones_NNS have_VBP been_VBN
        composed_VBN of_IN calcium_NN phosphate_NN or_CC oxalate_NN [_NN 32_CD ]_NN ._.
        Alternatively_RB ,_, it_PRP is_VBZ possible_JJ that_IN both_DT SI_NNP and_CC lactase_NN are_VBP
        connected_VBN mechanistically_RB to_TO intestinal_NN calcium_NN homeostasis_NNS
        through_IN molecular_JJ interactions_NNS with_IN calcium_NN transporters_NNS ._.
        In_IN this_DT regard_NN ,_, SI_NNP ,_, lactase_NN ,_, and_CC the_DT receptor_NN for_IN 1_CD ,_, 25_CD
        OH-VitD_NNP 3_CD (_( VDR_NNP )_) share_NN transcriptional_NN regulation_NN through_IN the_DT
        homeodomain_NN transcription_NN factor_NN CDX_NNP 2_CD [_NN 33_CD 34_CD ]_NN ._. The_DT
        possibility_NN that_IN SI_NNP or_CC lactase_NN deficiency_NN could_MD cause_VB
        secondary_JJ up-regulation_JJ of_IN VDR_NNP awaits_VBZ exploration_NN in_IN cell_NN
        culture_NN or_CC animal_NN models_NNS ._.
      
      
        Conclusions_NNP
        We_PRP conclude_VBP that_IN SI_NNP deficiency_NN should_MD be_VB added_VBN to_TO the_DT
        list_NN of_IN disorders_NNS that_WDT can_MD cause_VB infantile_JJ hypercalcemia_NN
        and_CC particularly_RB may_MD be_VB considered_VBN when_WRB accompanied_VBN by_IN FTT_NNP
        and_CC watery_JJ diarrhea_NN ._. In_IN addition_NN ,_, infants_NNS with_IN SI_NNP
        deficiency_NN should_MD have_VB careful_JJ monitoring_NN of_IN serum_NN calcium_NN ._.
        Prolonged_NNP periods_NNS of_IN diet_NN noncompliance_NN may_MD increase_VB the_DT
        risk_NN of_IN chronic_JJ renal_JJ disease_NN secondary_JJ to_TO
        nephrocalcinosis_NNS ._. Infants_NNS presenting_VBG with_IN persistent_JJ ,_,
        watery_JJ diarrhea_NN should_MD be_VB evaluated_VBN for_IN SI_NNP ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP contributions_NNS
        JWB_NNP -_: provided_VBN care_NN during_IN second_JJ admission_NN ,_, composed_VBN
        the_DT manuscript_NN
        BR_NNP -_: provided_VBN care_NN during_IN second_JJ admission_NN ,_, performed_VBN
        endoscopy_NN ,_, and_CC made_VBD the_DT primary_JJ diagnosis_NN
        WT_NNP -_: provided_VBN long_JJ term_NN primary_JJ care_NN including_VBG
        longitudinal_NN followup_NN
        SSB_NNP -_: performed_VBN and_CC interpreted_VBD the_DT specialized_JJ
        diagnostic_JJ enzyme_NN assays_NNS
        WHM_NNP -_: performed_VBN and_CC interpreted_VBD the_DT nuclear_JJ medicine_NN
        imaging_NN studies_NNS
        MCM_NNP -_: performed_VBN and_CC interpreted_VBD the_DT neuroimaging_VBG
        studies_NNS
        SMB_NNP -_: provided_VBN dietary_JJ management_NN during_IN and_CC after_IN
        second_JJ hospitalization_NN
        NLG_NNP -_: provided_VBN anaesthesia_NN care_NN and_CC coordinated_VBN multiple_JJ
        procedures_NNS during_IN second_JJ hospitalization_NN
        IDS_NNP -_: evaluated_VBN /_NN managed_VBD the_DT patient_NN primarily_RB and_CC
        contributed_VBD /_NN edited_JJ much_JJ of_IN the_DT manuscript_NN
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
